KRN7000 Applications
KRN7000 has wide research and human therapeutic applications. Below are a few examples of current research being applied with KRN7000.
- Adipose research
Adjuvant research - Antimicrobial research
- Asthma research
- Atherosclerosis research
- Breast cancer research
- Colitis research
- Colorectal cancer research
- Dendritic cells research
- Diabetes research
- Fatty acid amide hydrolase research
- Head and neck carcinoma
- Hepatic research
- Human T-lymphotropic virus type 1 (HTLV-1)
- Immune regulation
- immunology research
- Influenza A virus research
- Functional iNKT cells found in horse, pig, elephant and guinea pig
- Gaucher disease research
- Leukemia research
- Lung cancer research
- Lupus research
- Malaria research
- Melanoma metastases research
- Microbiology research
- Multiple sclerosis research
- Nanoparticles without inducing anergy effect
- Ocular research
- Ovarian tumors
- Rheumatoid arthritis
- Sarcoidosis research
- Tuberculosis research
- Japan research
Multiple sclerosis application: Synthetic glycolipid ligands as novel therapeutics for multiple sclerosis
Adjuvant application: Adjuvant effect of alpha-galactosylceramide (alpha-GalCer) in mice upon intravenous administration of antigen plus alpha-GalCer.
Diabetes application: NKT cell activation by Alpha-galactosylceramide (Alpha-GalCer) inhibits autoimmune diabetes in NOD mice
Hepatic application: Preactivation of NKT cells with Alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor
Diabetes type 1 application: Alpha-GalCer C20:2 May be a More Efficacious Candidate Drug Than alpha-GalCer C26:0 (KRN7000) for iNKT Cell Mediated Protection from Type 1 Diabetes
Head and neck carcinoma application: Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
Lupus application: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus
Adjuvant application: The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
Influenza A virus application: Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection
Hepatic application: Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Lung cancer application: A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer
Rheumatoid arthritis application: Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway
Ovarian tumor application: Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors
Colon cancer application: Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer
Leukemia application: Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells
Tuberculosis application: Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin
Tuberculosis application: Activation of NKT cells protects mice from tuberculosis
Dendritic cell application: Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells
Sarcoidosis application: Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis
Colorectal cancer application: Treatment of hepatic metastasis of the Colon26 adenocarcinoma with an α-galactosylceramide, KRN7000
Antimicrobial application: Cd1d-dependent regulation of bacterial colonization in the intestine of mice
Breast cancer application: Alpha-Galactosylceramide (KRN7000) suppression ofchemical- and oncogene-dependent carcinogenesis
Experimental autoimmune uveitis application: Activation of iNKT Cells Amerilorates Experimental Ocular Autoimmunity by a Mechanism Involving Innate IFN-γ Production and Dapening of the Adadtive Th1 and Th17 Responses
Colitis application: Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice
Human T-lymphotropic virus type 1 (HTLV-1) application: Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders
Malaria and Melanoma applications: Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand Alpha-Galactosylceramide
Asthma application: Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma
NKT cells identified in other animals: Functional iNKT cells found in other animals: Functional CD1d and/or NKT cell invariant chain transcript in horse, pig, African elephant and guinea pig, but not in ruminants
Resistance against tumor cells research: Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice
Immunology research: Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity
Immune regulation derivative research: Induction of Th1-biased cytokine production by Alpha-carba-GalCer, a neoglycolipid ligand for NKT cells
Nanoparticles without inducing anergy research: Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy
Atherosclerosis research: Effect of natural killer T cell activation on the initiation of atherosclerosis
